https://www.youtube.com/watch?v=pTIVORH7anc This video from Wochit News is all about a new treatment for severe hemophilia A. The Children’s Hospital of Los Angeles, California, has developed a breakthrough treatment that can reduce the bleeding episodes in people living with hemophilia A by up to 90 percent. MORE: Emicizumab shows…
Search results for:
An enzyme called activate protein C (APC), which prevents the formation of blood clots and therefore promotes bleeding could be targeted to treat hemophilia, suggests a study conducted by researcher at the University of Cambridge and the Children’s Hospital of Philadelphia.
Hemophilia B is a rare genetic bleeding disorder that impairs the blood’s ability to clot properly.
Connecting with others affected by hemophilia B can help you find a community with whom you can share what it’s like living with hemophilia B, including talking about daily life, symptoms, and treatments.
Receiving a hemophilia diagnosis can leave patients and their caregivers with many unanswered questions about the disease. Many want to know how to find information, connect with other patients and families, and get support. Here are answers to some frequently asked questions about hemophilia: What is hemophilia?…
When parenting a child with hemophilia, it’s important to understand how you can support them as they learn to live with the bleeding disorder. The two most common types of hemophilia, type A and type B, primarily affect males, while hemophilia C affects both…
While hemophilia A and hemophilia B are both bleeding disorders characterized by deficiencies in blood clotting factors, there are differences in one type versus the other, particularly in the specific genetic mutations that cause the disease, and in some of the treatment methods.
A first patient in the U.S. has enrolled in a multinational study to collect real-world data on different approaches in managing hemophilia A in people with inhibitors, with an aim of understanding how treatment decisions affect patients. The investigator-led MOTIVATE study (NCT04023019; EudraCT No. 2019-003427-38) is recruiting…